U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Transitional cell carcinoma of the bladder

MedGen UID:
76013
Concept ID:
C0279680
Neoplastic Process
Synonym: Transitional cell bladder carcinoma
SNOMED CT: Transitional cell carcinoma of bladder (255109008); TCC - Transitional cell carcinoma of bladder (255109008)
 
HPO: HP:0006740
Monarch Initiative: MONDO:0005611

Definition

The presence of a carcinoma of the urinary bladder with origin in a transitional epithelial cell. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVTransitional cell carcinoma of the bladder

Conditions with this feature

Malignant tumor of urinary bladder
MedGen UID:
14150
Concept ID:
C0005684
Neoplastic Process
A primary or metastatic malignant neoplasm involving the bladder.
Colorectal cancer
MedGen UID:
83428
Concept ID:
C0346629
Neoplastic Process
Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.
PTEN hamartoma tumor syndrome with granular cell tumor
MedGen UID:
400984
Concept ID:
C1866376
Neoplastic Process
Cowden syndrome 5
MedGen UID:
767432
Concept ID:
C3554518
Disease or Syndrome
PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia. Prior to the identification of PIK3CA as the causative gene, PROS was separated into distinct clinical syndromes based on the tissues and/or organs involved (e.g., MCAP [megalencephaly-capillary malformation] syndrome and CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome). The predominant areas of overgrowth include the brain, limbs (including fingers and toes), trunk (including abdomen and chest), and face, all usually in an asymmetric distribution. Generalized brain overgrowth may be accompanied by secondary overgrowth of specific brain structures resulting in ventriculomegaly, a markedly thick corpus callosum, and cerebellar tonsillar ectopia with crowding of the posterior fossa. Vascular malformations may include capillary, venous, and less frequently, arterial or mixed (capillary-lymphatic-venous or arteriovenous) malformations. Lymphatic malformations may be in various locations (internal and/or external) and can cause various clinical issues, including swelling, pain, and occasionally localized bleeding secondary to trauma. Lipomatous overgrowth may occur ipsilateral or contralateral to a vascular malformation, if present. The degree of intellectual disability appears to be mostly related to the presence and severity of seizures, cortical dysplasia (e.g., polymicrogyria), and hydrocephalus. Many children have feeding difficulties that are often multifactorial in nature. Endocrine issues affect a small number of individuals and most commonly include hypoglycemia (largely hypoinsulinemic hypoketotic hypoglycemia), hypothyroidism, and growth hormone deficiency.
Cowden syndrome 6
MedGen UID:
767433
Concept ID:
C3554519
Disease or Syndrome
\n\nThe features of Cowden syndrome overlap with those of another disorder called Bannayan-Riley-Ruvalcaba syndrome. People with Bannayan-Riley-Ruvalcaba syndrome also develop hamartomas and other noncancerous tumors.  Some people with Cowden syndrome have relatives diagnosed with Bannayan-Riley-Ruvalcaba syndrome, and other affected individuals have the characteristic features of both conditions. Based on these similarities, researchers have proposed that Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent a spectrum of overlapping features known as PTEN hamartoma tumor syndrome (named for the genetic cause of the conditions) instead of two distinct conditions.\n\nSome people do not meet the strict criteria for a clinical diagnosis of Cowden syndrome, but they have some of the characteristic features of the condition, particularly the cancers. These individuals are often described as having Cowden-like syndrome. Both Cowden syndrome and Cowden-like syndrome are caused by mutations in the same genes.\n\nCowden syndrome is associated with an increased risk of developing several types of cancer, particularly cancers of the breast, a gland in the lower neck called the thyroid, and the lining of the uterus (the endometrium). Other cancers that have been identified in people with Cowden syndrome include kidney cancer, colorectal cancer, and an agressive form of skin cancer called melanoma. Compared with the general population, people with Cowden syndrome develop these cancers at younger ages, often beginning in their thirties or forties. People with Cowden syndrome are also more likely to develop more than one cancer during their lifetimes compared to the general population. Other diseases of the breast, thyroid, and endometrium are also common in Cowden syndrome. Additional signs and symptoms can include an enlarged head (macrocephaly) and a rare, noncancerous brain tumor called Lhermitte-Duclos disease. A small percentage of affected individuals have delayed development, intellectual disability, or autism spectrum disorder, which can affect communication and social interaction.\n\nAlmost everyone with Cowden syndrome develops hamartomas. These growths are most commonly found on the skin and mucous membranes (such as the lining of the mouth and nose), but they can also occur in the intestine and other parts of the body. The growth of hamartomas on the skin and mucous membranes typically becomes apparent by a person's late twenties.\n\nCowden syndrome is a genetic disorder characterized by multiple noncancerous, tumor-like growths called hamartomas and an increased risk of developing certain cancers.

Professional guidelines

PubMed

Bournakis E, Dimopoulos MA, Bamias A
Expert Rev Anticancer Ther 2011 Jun;11(6):931-9. doi: 10.1586/era.10.197. PMID: 21707290
Walsh DL, Chang SS
Urol Oncol 2009 Jul-Aug;27(4):352-7. Epub 2008 Apr 24 doi: 10.1016/j.urolonc.2007.12.010. PMID: 18439852
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG
J Clin Oncol 2001 Feb 1;19(3):666-75. doi: 10.1200/JCO.2001.19.3.666. PMID: 11157016

Recent clinical studies

Etiology

Phillips RM, Hendriks HR, Peters GJ; EORTC-Pharmacology and Molecular Mechanism Group
Br J Pharmacol 2013 Jan;168(1):11-8. doi: 10.1111/j.1476-5381.2012.01996.x. PMID: 22509926Free PMC Article
Walsh DL, Chang SS
Urol Oncol 2009 Jul-Aug;27(4):352-7. Epub 2008 Apr 24 doi: 10.1016/j.urolonc.2007.12.010. PMID: 18439852
Sengupta S, Blute ML
Urology 2006 Mar;67(3 Suppl 1):48-54; discussion 54-5. doi: 10.1016/j.urology.2006.01.041. PMID: 16530076
Lapham RL, Ro JY, Staerkel GA, Ayala AG
Semin Surg Oncol 1997 Sep-Oct;13(5):307-18. doi: 10.1002/(sici)1098-2388(199709/10)13:5<307::aid-ssu4>3.0.co;2-h. PMID: 9259086
Hoenig DM, McRae S, Chen SC, Diamond DA, Rabinowitz R, Caldamone AA
J Urol 1996 Jul;156(1):203-5. PMID: 8648805

Diagnosis

ElSharnoby O, Fraser N, Williams A, Scriven S, Shenoy M
J Pediatr Surg 2022 Jul;57(7):1409-1413. Epub 2021 Sep 17 doi: 10.1016/j.jpedsurg.2021.09.007. PMID: 34563358
Martyn-Hemphill C, Mak D, Khan MS, Challacombe BJ, Bishop CV
Int J Surg 2013;11(9):749-52. Epub 2013 Sep 5 doi: 10.1016/j.ijsu.2013.08.018. PMID: 24013072
Walsh DL, Chang SS
Urol Oncol 2009 Jul-Aug;27(4):352-7. Epub 2008 Apr 24 doi: 10.1016/j.urolonc.2007.12.010. PMID: 18439852
Kurth KH
Eur Urol 1997;31 Suppl 1:10-9. doi: 10.1159/000474526. PMID: 9076481
Hoenig DM, McRae S, Chen SC, Diamond DA, Rabinowitz R, Caldamone AA
J Urol 1996 Jul;156(1):203-5. PMID: 8648805

Therapy

Liu Z, Lai J, Jiang H, Ma C, Huang H
FASEB J 2021 Jun;35(6):e21603. doi: 10.1096/fj.202100054RR. PMID: 33999448
Phillips RM, Hendriks HR, Peters GJ; EORTC-Pharmacology and Molecular Mechanism Group
Br J Pharmacol 2013 Jan;168(1):11-8. doi: 10.1111/j.1476-5381.2012.01996.x. PMID: 22509926Free PMC Article
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative
J Urol 2004 Feb;171(2 Pt 1):561-9. doi: 10.1097/01.ju.0000090967.08622.33. PMID: 14713760
Ryan CW, Vogelzang NJ
Expert Opin Pharmacother 2000 Mar;1(3):547-53. doi: 10.1517/14656566.1.3.547. PMID: 11249537
Lamm DL
Urol Clin North Am 1992 Aug;19(3):499-508. PMID: 1636234

Prognosis

Liu Z, Lai J, Jiang H, Ma C, Huang H
FASEB J 2021 Jun;35(6):e21603. doi: 10.1096/fj.202100054RR. PMID: 33999448
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative
J Urol 2004 Feb;171(2 Pt 1):561-9. doi: 10.1097/01.ju.0000090967.08622.33. PMID: 14713760
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG
J Clin Oncol 2001 Feb 1;19(3):666-75. doi: 10.1200/JCO.2001.19.3.666. PMID: 11157016
Hoenig DM, McRae S, Chen SC, Diamond DA, Rabinowitz R, Caldamone AA
J Urol 1996 Jul;156(1):203-5. PMID: 8648805
Lamm DL
Urol Clin North Am 1992 Aug;19(3):499-508. PMID: 1636234

Clinical prediction guides

ElSharnoby O, Fraser N, Williams A, Scriven S, Shenoy M
J Pediatr Surg 2022 Jul;57(7):1409-1413. Epub 2021 Sep 17 doi: 10.1016/j.jpedsurg.2021.09.007. PMID: 34563358
Liu Z, Lai J, Jiang H, Ma C, Huang H
FASEB J 2021 Jun;35(6):e21603. doi: 10.1096/fj.202100054RR. PMID: 33999448
Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J
J Urol 2000 Jan;163(1):73-8. doi: 10.1016/s0022-5347(05)67975-x. PMID: 10604317
Esrig D, Freeman JA, Stein JP, Skinner DG
Semin Urol Oncol 1997 Aug;15(3):154-60. PMID: 9394910
Ozen H
Curr Opin Oncol 1994 May;6(3):313-7. doi: 10.1097/00001622-199405000-00015. PMID: 8080861

Recent systematic reviews

Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration
Cochrane Database Syst Rev 2006 Apr 19;2006(2):CD006018. doi: 10.1002/14651858.CD006018. PMID: 16625650Free PMC Article
Advanced Bladder Cancer Overview Collaboration
Cochrane Database Syst Rev 2005 Apr 18;2004(2):CD005246. doi: 10.1002/14651858.CD005246. PMID: 15846746Free PMC Article
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative
J Urol 2004 Feb;171(2 Pt 1):561-9. doi: 10.1097/01.ju.0000090967.08622.33. PMID: 14713760

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...